Search results
Results From The WOW.Com Content Network
(Reuters) -Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, Absci ...
September 26, 2024 at 9:05 AM. (Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer ...
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc., an independent subsidiary of AstraZeneca, is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders ...
Durvalumab, [8] sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. [9] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1 (CD279).
If approved for HER2 low and ultra-low breast cancers after endocrine therapy, eight out of out 10 women with metastatic breast cancer could be treated with Enhertu, AstraZeneca oncology research ...
AstraZeneca plc (/ ˌæstrəˈzɛnəkə /) (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [2][3][4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection ...
In 2019 AstraZeneca agreed to pay up to US$6.9 billion to jointly develop DS-8201 with Japan's Daiichi Sankyo. It is intended to replace Herceptin for treating breast cancer. DS8201 carries eight payloads, compared to the usual four. [2]
All of this means the company is gearing up for several launches and label expansions — and new revenue streams. AstraZeneca has set a target to become an $80 billion company, in sales, by 2030.